𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The validity and reliability of the Turkish versii̇on of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects

✍ Scribed by H. Mavioglu; M. Gedizlioglu; S. Akyel; T. Aslaner; E. Eser

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
80 KB
Volume
21
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objectives

The cognitive subscale of the Alzheimer's Disease Assesment Scale (ADAS‐Cog) is the most widely used test in clinical trials dealing with Alzheimer's disease (AD). The aim of this study was to investigate the validity and reliability of the Turkish version of ADAS‐Cog.

Methods

Twenty‐nine patients with AD, fullfilling NINCDS‐ADRDA criteria of probable AD, who were in stage 3–5 according to the Global Deterioration Scale (GDS), and 27 non‐demented control subjects with similar age, gender and educational status were recruited for the study. The Turkish version of ADAS‐Cog, Standardized Mini Mental Status Examination (MMSE) and Short Orientation‐Memory‐Concentration Test (SOMCT) were applied to both of the groups. Inter‐rater reliability, internal consistency, test–retest reliability; face validity, differential validity and convergent validity were statistically analyzed.

Results

Both MMSE and ADAS‐Cog have significantly differentiated patients with AD and control subjects (p < 0.001). A significant correlation was established between MMSE and ADAS‐Cog scores in AD group (r: −0.739). ADAS‐Cog was also highly significantly correlated with GDS (r: 0.720) and SOMCT (r: 0.738). For the group with AD, control and whole cohort coefficients of internal consistency, Cronbach's α: 0.800, 0.515, 0.873 were found respectively. Inter‐rater reliability for total ADAS‐Cog score was found as ICC: 0.99 and 0.98 and test–retest reliability was found as ICC: 0.91 and 0.95 for demented and nondemented subjects, respectively.

Conclusion

The Turkish version of ADAS‐Cog has been found to be highly reliable and valid in differentiating patients with mild and moderate AD from nondemented subjects. Copyright © 2006 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Detecting treatment effects with combina
Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease
✍ Ralf Ihl; Steven Ferris; Philippe Robert; Bengt Winblad; Serge Gauthier; Frank T 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 2 views

## Abstract ## Objective When complex cognitive functions are measured with multi‐item scales like the Alzheimer's Disease Assessment Scale – cognitive subscale (ADAS‐cog), it seems valuable information can be lost due to combination of the ADAS‐cog items results into a total score. We hypothesize

Assessing response to tacrine using the
Assessing response to tacrine using the factor analytic structure of the Alzheimer's disease assessment scale (Adas)—cognitive subscale
✍ Dr. Jason T. Olin; Lon S. Schneider 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 344 KB

A factor analysis of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADASc), the primary cognitive outcome measure in most clinical trials of drugs for Alzheimer's disease, was undertaken to test whether factor scores are differentially sensitive to change in a placebo-controlled 30-wee

Reliability and validity of the Japanese
Reliability and validity of the Japanese version of the Dysexecutive Questionnaire (DEX) in Alzheimer's disease: validation of a behavioral rating scale to assess dysexecutive symptoms in Japanese patients with Alzheimer's disease
✍ Yoshihiro Shinagawa; Shutaro Nakaaki; Jin Hongo; Yoshie Murata; Junko Sato; Teru 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

## Abstract ## Background Both executive cognitive dysfunction and behavioral problems contribute to dysexecutive symptoms in daily life. The aim of the present study was to develop a behavior rating scale for assessing dysexecutive symptoms in Japanese patients with AD. ## Method The Dysexecuti

A multinational, randomised, 12-week stu
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease
✍ Roy W. Jones; Hilkka Soininen; Klaus Hager; Dag Aarsland; Peter Passmore; Anita 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 1 views

## Abstract ## Objectives To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL). ## Methods Pati

Effects of memantine on cognition in pat
Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies
✍ Patrizia Mecocci; Anna Bladström; Karina Stender 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB 👁 1 views

## Abstract ## Objectives The post‐hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS‐cog single‐items or SIB subscales for patients with moderate to severe AD. ## Methods Data from six multicentre, randomised, placebo‐controlled, parallel‐group, double‐blind